NanoViricides, Inc. (NYSE American: NNVC) announced that a Phase II clinical trial of its antiviral candidate NV-387 for the treatment of MPox is expected to begin soon in the Democratic Republic of Congo, with site preparation and staff training scheduled for early April 2026. The study, already approved by the DRC regulatory agency, will evaluate the safety and effectiveness of NV-387 against Clade I MPox, as the company advances regulatory development and seeks Orphan Drug Designation from the U.S. FDA.
The trial represents a critical step in addressing MPox, particularly the Clade I strain which has been associated with higher mortality rates. NV-387 is a broad-spectrum antiviral drug that NanoViricides is also developing for respiratory viral infections including RSV, COVID-19, Long COVID, and influenza. The company’s novel nanoviricide technology platform aims to create targeted nanomaterials that can attack viruses directly, potentially offering a new class of antiviral therapies.
According to the company, the DRC regulatory body has already approved the trial protocol, and preparations are underway to initiate patient enrollment. The Phase II study will focus on evaluating the safety and efficacy of NV-387 in patients infected with Clade I MPox, which is more severe than the Clade II strain responsible for the 2022 global outbreak. NanoViricides is also pursuing Orphan Drug Designation from the U.S. FDA, which could provide incentives such as tax credits and market exclusivity upon approval.
This development is significant given the ongoing MPox outbreaks in Africa and the need for effective treatments. The World Health Organization has declared MPox a public health emergency of international concern, and the availability of a targeted antiviral could help curb transmission and reduce mortality. NanoViricides’ approach using nanoviricide technology may offer advantages over existing treatments, such as improved delivery and reduced side effects.
The company’s lead drug candidate NV-387 is designed to work by mimicking host cell receptors, thereby binding to viruses and neutralizing them. This mechanism is distinct from traditional small molecule antivirals and could potentially be effective against multiple viral strains. NanoViricides has previously reported positive preclinical data for NV-387 against MPox and other viruses.
For more information, see the full press release at https://ibn.fm/4Ckhk. Updates on NanoViricides are available in the company’s newsroom at https://ibn.fm/NNVC.
The initiation of this Phase II trial marks a pivotal moment for NanoViricides as it transitions from preclinical to clinical development. Success in this study could pave the way for regulatory submissions and potentially provide a new therapeutic option for MPox patients. The company’s focus on Clade I MPox addresses an unmet medical need, particularly in regions like the DRC where healthcare infrastructure is limited.
Investors and public health officials will be watching the trial’s progress closely, as positive results could validate the nanoviricide platform and open doors for broader applications. However, as with all drug development, there are no guarantees of success, and the company acknowledges the lengthy and capital-intensive nature of the process.
